Treatment of PD-1 Inhibitor in AIDS-associated PML (TPAP)
The Effect and Safety of Programmed Cell Death Protein 1 (PD-1) Inhibitor on AIDS Patients With Progressive Multifocal Leukoencephalopathy (PML): A One-center, Single-arm and Prospective Study
Sponsor: First Affiliated Hospital of Zhejiang University
A PHASE2 clinical study on AIDS and Progressive Multifocal Leukoencephalopathy, this trial is ongoing. The trial is conducted by First Affiliated Hospital of Zhejiang University and has accumulated 5 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital of Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .